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Background: Alpha-fetoprotein (AFP)-producing pancreatic neuroendocrine tumors (pNETs) are rare, and the few
reported cases usually coexisted with other malignant components such as adenocarcinoma or hepatoid
carcinoma. We present here the first case of pure AFP-producing pNET.
Case presentation: A 56-year-old male patient underwent resection of the pancreatic tail and body because of
elevated serum AFP levels and pancreatic mass. Microscopy showed that the tumor tissue consisted of large and
small solid nests of polygonal cells. The tumor cells were positive for chromogranin A, synaptophysin, CD99,
cytokeratin 19, pan-cytokeratin and β-catenin, and also showed diffuse immunoreactivity for AFP and human
chorionic gonadotrophin. The mitotic rate was nearly 30 per 10 high-power fields and the Ki-67 index was nearly
25%. The histopathologic findings supported the diagnosis of an AFP-producing pNET. Other malignant components
were not found. Serum AFP levels decreased to near-normal after operation and gradually increased to >1000 ng/ml
at 5 months post-surgery. Recurrence and hepatic metastases were revealed by computed tomography. The patient
died 21 months after surgery.
Conclusion: This was the first case of pure AFP-producing pNET to be reported in the English literature. Serum AFP
levels may provide useful information for monitoring the therapeutic effectiveness, early recurrence or metastases.
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Pancreatic neuroendocrine tumors (pNETs) are rare ma-
lignant tumors of the pancreas and account for approxi-
mately 1-2% of all pancreatic neoplasms [1,2]. The
origin of pNETs is not completely understood, but these
tumors may arise from pluripotent stem cells within the
exocrine pancreas [3]. pNETs may be divided into func-
tional and nonfunctional tumors according to whether
or not there is an associated clinical syndrome caused by
the release of biologically active peptides. Because there
are no specific clinical symptoms associated with non-
functional pNETs, these neoplasms are frequently found
incidentally and diagnosed at late stages [4,5].
Alpha-fetoprotein (AFP) has long been used as a
tumor marker for hepatocellular carcinoma (HCC) and* Correspondence: zldrysn@163.com
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unless otherwise stated.embryonic cell tumors. Elevated serum levels of AFP
were also found in patients with carcinoma metastasis to
the liver or non-neoplastic liver injury. Several cases of
pNETs with elevated serum AFP levels have been re-
ported, but most of these cases had liver metastasis at
the time of diagnosis [6-8]. Rare cases of AFP-producing
pNETs have been described in the English literature
[9-14], but these tumors usually coexisted with other
malignant components such as adenocarcinoma or
hepatoid carcinoma. Here, we present the first case of
pure AFP-producing pNET, in which the AFP-producing
site was immunohistochemically confirmed in the tumor
tissues. The clinico-pathological characteristics of this
tumor were evaluated, and the literature about AFP-
producing pNETs was reviewed.
Case presentation
Clinical course
A 56-year-old man was admitted to the Peking University
Third Hospital in December of 2011 because of abnormalis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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during routine health checkup. He had no symptoms of
hypoglycemia, diarrhea or abdominal pain. Fifteen months
earlier, he suffered from a liver abscess with normal serum
AFP, which was treated successfully with antibiotics. Chole-
cystolithiasis was diagnosed at that time. One month earl-
ier, he had undergone laparoscopic cholecystectomy for
gallstones at another hospital. Enlargement of the tail and
body of the pancreas was demonstrated by computed tom-
ography (CT), and a diagnosis of pancreatitis was consid-
ered. The patient did not smoke but drank alcohol
occasionally. Physical examination on admission revealed
no specific findings.
Laboratory tests showed that serum AFP levels were
elevated to 321.4 ng/ml (normal: 0–20 ng/ml). The
levels of other tumor markers (carcinoembryonic antigen
[CEA], carbohydrate antigen 19–9 [CA199], carbohy-
drate antigen 125, and prostatic antigens) were all within
normal limits. There was no serologic evidence of hepa-
titis B or C. Blood cell counts, erythrocyte sedimentation
rate, and coagulation tests were normal. Levels of serum
aminotransferases, alkaline phosphatase, gamma-glutamyl
transferase, albumin, urea nitrogen, creatinine, amylase,
lipase, glucose, human chorionic gonadotrophin (HCG),
and immunoglobulins were all normal. Testicular ultrason-
ography revealed a cystic mass in the left epididymidis.Figure 1 Imaging examinations. MRI showed enlargement of the pancre
Some enlarged peripancreatic lymph nodes were noted (A, B). Abdominal
appeared to be hypoattenuated with an unclear margin. A mass measuring
observed in the enlarged pancreas on contrast-enhanced CT (C, D). None
The main pancreatic duct, common bile duct, and intrahepatic bile ducts wImaging examinations are shown in Figure 1. Abdom-
inal CT revealed diffuse enlargement of the body and tail
of the pancreas, which appeared as a region of low-
attenuation with an indistinct margin. A mass measuring
5.2 × 4.8 × 4.1 cm showing probable encasement of the
splenic vein was found in the enlarged pancreas by
contrast-enhanced CT. Magnetic resonance imaging
confirmed enlargement of the body and tail of the pan-
creas with poor enhancement after gadolinium adminis-
tration. Some enlarged peripancreatic lymph nodes were
also noted. None of the imaging examinations showed
abnormal findings in the liver. The main pancreatic
duct, common bile duct, and intrahepatic bile ducts
were normal on endoscopic retrograde cholangiopan-
creatography. The patient underwent a resection of the
tail and body of the pancreas, splenectomy, and resec-
tion of four regional lymph nodes in January 2012. No
metastatic neoplasm was found on the liver surface or in
lymph nodes during surgery.
Histopathological findings
Grossly, a grey ill-define nodular mass, measuring 5 ×
4.5 × 3.5 cm, was shown at the body and tail of the
pancreas (Figure 2). Necrosis, hemorrhage and parapan-
creatic adipose tissues invasion were observed. Light mi-
croscopy revealed that the tumor tissue consisted ofas body and tail with poor enhancement after gadolinium injection.
CT revealed diffuse enlargement of the pancreas body and tail, which
5.2 × 4.8 × 4.1 cm with probable encasement of the splenic vein was
of the imaging examinations revealed abnormal findings in the liver.
ere normal on endoscopic retrograde cholangiopancreatography (E).
Figure 2 Histopathological findings. The tumor was predominantly composed of circumscribed cellular islands (A, 100×) comprised of large
and small solid nests of polygonal cells that had moderate amounts of cytoplasm, and round to oval nuclei with minimal to moderate atypia
(B, 400×). The mitotic cells were easy to find. The tumor cells widely expressed pan-cytokeratin, which appeared as typical dot-like positive on the
nuclear side (C, 400×). CgA expression was patchy (D, 400×). Tumor cells exhibited partial strong AFP immunoreactivity with a granular pattern
(E, 400×). Tumor cells focally showed strong HCG immunoreactivity (F, 400×). Transmission electron microscopic examination showed that the
tumor cells contained electron-dense neuroendocrine granules measuring 230 nm in diameter (G).
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tering of pancreas islets among them. No residual pan-
creatic tissue was found within the tumor. The tumor
cells had moderate amounts, granular and eosinophilic
cytoplasm, and round to oval nuclei with mild to moder-
ate atypia. One or two red, moderately sized nucleoli
were noted in some tumor cells. The mitotic rate was
nearly 30 per 10 high-power fields. There was no differ-
entiated component characteristic of adenocarcinoma,
acinar cell carcinoma or hepatoid carcinoma of the pan-
creas. The surgical margins were negative for neoplastic
infiltration. There was no evidence of vascular or peri-
neural invasion. No lymph node metastasis was shown.
Transmission electron microscopy showed that the tumor
cells contained electron-dense neuroendocrine granules
measuring 230 nm in diameter.
Immunohistochemistry showed patchy expression of
chromogranin A (CgA) and synaptophysin (Syn). Tumorcells also showed diffuse immunoreactivity for AFP and
focal strong immunoreactivity for hCG. Dot-like pan-
cytokeratin (CKpan) reactivity near the nucleus, β-catenin
reactivity at the cell membrane, diffuse CD99 expression in
cytoplasm, and wide CK19 expression in tumor cells were
observed. There was no expression of HapPar-1, CD10,
CD56, or progesterone receptor (PR) in tumor cells. Ki-67
index was nearly 25%. The histopathology findings sup-
ported the diagnosis of a pure AFP-producing neuroendo-
crine carcinoma according to the forth edition of WHO
Classification of neuroendocrine tumors [15].
Follow-up
Serum AFP levels decreased to 23.15 ng/ml on day 29
post-surgery, but increased to 180.9 ng/ml on day 80.
Lymph nodes metastasis and a recurrent mass in the re-
sidual pancreas were detected by CT. The patient was
treated with a somatostatin (SS) analog (Sandostatin
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creased to 1200 ng/ml 5 months after surgery, and liver
metastases were found on CT. Hepatic metastases were
treated with hepatic artery embolization and percutan-
eous radiofrequency ablation (RFA) in another hospital,
and the serum AFP levels fluctuated around 700 ng/ml.
His clinical condition gradually worsened, and he died
21 months after the original surgery. Other tumor markers
(such as CEA and CA19-9) remained within the normal
range during follow-up.
Discussion
AFP is a tumor marker for HCC and had been used in the
clinical practice for a long time. Because there is a large
population of patients with hepatitis B or C virus infection in
China, serum levels of AFP are measured routinely during
health checkups to screen for HCC. The high levels of AFP
in this patient originally raised the question as to whether
there was a tumor or another condition causing the expres-
sion of AFP.
Pancreatic neuroendocrine neoplasms are rare, sporadic
pancreatic tumors. Many pNETs are diagnosed at late
stages because of the lack of symptoms in the case of non-
functional tumors. The apparent incidence of pNETs had
increased in recent years, likely due to improved detection
methods, but it is still difficult to diagnosis pNETs at an
early stage when the tumor do not invade adjacent tissues
or produce distant metastases [1,2]. Histologically, pNETs
consist of relatively homogeneous, small, round cells with
uniform nuclei and cytoplasm. The expression of CgA is
widely used to identify gastrointestinal NETs [16].
Only 23 cases of pNETs with elevated serum AFP levels
have been described in the English literatures, and liver me-
tastases were confirmed in most of these patients [6-14].
Among these cases, the AFP-producing sites were identified
by immunohistochemical examination of the resected tumor
in 7 cases only (see Table 1, including the current case).
Interestingly, the presence of another malignant component
such as adenocarcinoma (1 case) or hepatoid carcinoma (5
cases) coexisted with the neuroendocrine neoplasm in allTable 1 Studies of AFP-producing pNETs or AFP-producing pa
confirmed by immunohistochemistry
Study Year of publication Age/sex Location Other c
Paner et al. [9] 2000 57/M Tail Hepatoid
Lam et al. [10] 2001 64/F Tail Hepatoid
Oh et al. [11] 2006 21/M Head Hepatoid
Hameed et al. [12] 2007 41/F Head Hepatoid
Brandi et al. [13] 2008 68/F Tail/body Adenoca
Jung et al. [14] 2010 46/M Head Hepatoid
Present case NA 56/M Tail/body None
DOD: dead of disease; NA: not available.these 7 cases except the present case. In our case, there were
no histopathological features and patterns of immunoreactiv-
ity typically usually seen in carcinoma arising from pancreatic
ducts, acinar cell, or hepatoid carcinoma. To the best of our
knowledge, this is the first reported case of histologically-
confirmed pure AFP-producing pNET without another coex-
isting malignant component.
In the present case, tumor cells exhibited dot-like
CKpan reactivity near the nucleus, which is the classical
CK expression pattern in neuroendocrine tumors. CD56
is usually expressed in pNETs [17], but was negative in
this case. In the present case, tumor cells were positive
for β-catenin at the cell membrane, not in the nucleus.
Cells were diffusely positive for CD99 in the cytoplasm,
but dot-like immunoreactivity was not observed near the
nucleus. CD10 and PR were both negative. These findings
suggested that the tumor was not a solid-pseudopapillary
neoplasm of the pancreas. Previous studies described ele-
vated serum HCG levels in patients with pNETs [8,18]. In
the present case, serum HCG levels were normal, but
immunohistochemisrty for HCG was positive in the
resected tumor tissues.
Surgery is the only treatment that has the potential to
cure patients with pNETs. Although the present patient
was treated with radical surgery that achieved free resec-
tion margins and that did not exhibit regional lymph
node metastases, the tumor relapsed and metastasized
within months after surgery. More than 90% of pNETs
express SS receptors, and biotherapy with long-acting SS
analogs had been shown to slow tumor growth and im-
prove survival in patients with pNETs [19,20]. However,
recurrence and liver metastases were noted during the
course of SS analogs treatment in the present case, sug-
gesting that SS analogs are not always effective in pre-
venting tumor growth or metastasis. Treatments with
arterial embolization and percutaneous RFA for hepatic
metastases may prolong the patient’s life.
Pancreatic neuroendocrine neoplasms include well-differ-
entiated (low- to intermediate-grade) neuroendocrine tu-
mors and poorly differentiated (high-grade) neuroendocrinencreatic tumors with a neuroendocrine component
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mitoses per 10 high-power fields (and/or, >20% Ki67 index)
according to the WHO Classification of neuroendocrine neo-
plasms of the pancreas [15]. On the basis of morphological
criteria and the assessment of proliferation fraction, the grade
of present case was NEC. According to the TNM classifica-
tion system, the present case was Stage IIA (T3N0M0) at
diagnosis. The grade (based on the proliferation rate) and
stage (extent of disease) of this tumor were coincident.
In an analysis of the Surveillance Epidemiology and End
Results (SEER) database, the 5-year survival of patients with
poorly differentiated tumors was <38% for local disease,
21% for loco-regional disease, and <4% for metastatic dis-
ease, and the median survival for distant metastatic disease
was only 5 months in patients with poorly differentiated
carcinoma [21]. Some histological features such as necrosis,
expression of CK19 and loss of PR expression are important
factors for predicting the malignant behavior and prognosis
[15]. Several studies have suggested that patients with ele-
vated serum AFP levels have a poor prognosis, and liver
metastases were noted in most of these patients [6-9]. In
the present case, serum AFP levels were used as an indica-
tor of therapeutic effectiveness and a marker for monitoring
early recurrence and metastasis. The serum AFP levels ap-
parently correlated with the tumor burden and increasing
AFP levels might give a warning for timely interventions.
Conclusion
We described the first case of pure AFP-producing
pNEC. Serum AFP levels may provide useful information
for monitoring the therapeutic effectiveness, early recur-
rence or metastases.
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